UBS Maintains Buy on Cardinal Health, Raises Price Target to $134
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health and raised the price target from $125 to $134.
October 22, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health and increased the price target from $125 to $134, indicating a positive outlook.
The increase in price target from $125 to $134 by UBS suggests a positive outlook for Cardinal Health, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100